On October 20, 2020 Guido van Amerongen successfully defended his PhD thesis ‘Integrated assessment of neurocognitive, neurophysiological and pain processing in early clinical drug development’ at Leiden University!
Pain is a complex multifaceted process that involves many peripheral and central pharmacological systems. Guido’s thesis centres on the early development of two centrally acting analgesics that affect the endocannabinoid CB1 system and subtypes of GABAA receptors. In both cases, extensive profiling of neurocognitive, neurophysiological and pain processing was performed to provide further insights into the complicated interplays between CNS depression, acute nociception and pain experience. Integration of this information can be useful in the determination of the anticipated therapeutic window, the expected adverse effect profile and potential indications for subsequent clinical trials.
Guido was supervised by promotores Prof. dr. Joop van Gerven and Prof. dr. Adam Cohen, and co-promotor dr. Geert Jan Groeneveld.
Read Guido's thesis or contact us for more information.